6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
Complete regulatory breakdown of Jatenzo (oral testosterone undecanoate), including its FDA approval history, prescribing label specifics, compounding legal status under federal law, and what patients and clinicians need to know about access.
A detailed comparison of how the FDA and EMA evaluated oral testosterone undecanoate (Jatenzo), including approval timelines, label requirements, cardiovascular risk language, and post-market surveillance obligations.
A complete guide to Jatenzo (oral testosterone undecanoate) regulatory history: FDA approval date, REMS program, black-box warnings, labeling requirements, and post-market surveillance data.
A comprehensive timeline of every FDA label change to Jatenzo (oral testosterone undecanoate) from initial approval through 2026, including REMS requirements, cardiovascular warnings, and dosing revisions.
A clinical review of Jatenzo (oral testosterone undecanoate) covering its FDA approval history, patent litigation, labeling requirements, REMS considerations, and ongoing legal challenges facing Tolmar.
A clinical review of Jatenzo (oral testosterone undecanoate), its FDA approval history, current label, post-market safety data, and the next-generation oral TRT pipeline.